These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 26045797)

  • 1. Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations.
    López-Ayllón BD; de Castro-Carpeño J; Rodriguez C; Pernía O; Ibañez de Cáceres I; Belda-Iniesta C; Perona R; Sastre L
    Int J Clin Exp Pathol; 2015; 8(3):2888-98. PubMed ID: 26045797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
    Klughammer B; Brugger W; Cappuzzo F; Ciuleanu T; Mok T; Reck M; Tan EH; Delmar P; Klingelschmitt G; Yin AY; Spleiss O; Wu L; Shames DS
    J Thorac Oncol; 2016 Apr; 11(4):545-55. PubMed ID: 26773740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
    Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
    J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
    Demuth C; Madsen AT; Weber B; Wu L; Meldgaard P; Sorensen BS
    BMC Cancer; 2018 Feb; 18(1):191. PubMed ID: 29448920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
    Costa DB; Nguyen KS; Cho BC; Sequist LV; Jackman DM; Riely GJ; Yeap BY; Halmos B; Kim JH; Jänne PA; Huberman MS; Pao W; Tenen DG; Kobayashi S
    Clin Cancer Res; 2008 Nov; 14(21):7060-7. PubMed ID: 18981003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
    Yamamoto C; Basaki Y; Kawahara A; Nakashima K; Kage M; Izumi H; Kohno K; Uramoto H; Yasumoto K; Kuwano M; Ono M
    Cancer Res; 2010 Nov; 70(21):8715-25. PubMed ID: 20959484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
    Chin TM; Quinlan MP; Singh A; Sequist LV; Lynch TJ; Haber DA; Sharma SV; Settleman J
    Clin Cancer Res; 2008 Nov; 14(21):6867-76. PubMed ID: 18980981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer.
    Park CK; Oh IJ; Choi YD; Jang TW; Lee JE; Ryu JS; Lee SY; Kim YC
    Oncology; 2018; 94(6):373-382. PubMed ID: 29502124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
    Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
    Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
    Kelly K; Altorki NK; Eberhardt WE; O'Brien ME; Spigel DR; Crinò L; Tsai CM; Kim JH; Cho EK; Hoffman PC; Orlov SV; Serwatowski P; Wang J; Foley MA; Horan JD; Shepherd FA
    J Clin Oncol; 2015 Dec; 33(34):4007-14. PubMed ID: 26324372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.
    Winther-Larsen A; Nissen PH; Jakobsen KR; Demuth C; Sorensen BS; Meldgaard P
    Lung Cancer; 2015 Nov; 90(2):314-20. PubMed ID: 26386832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
    Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
    BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
    Pietanza MC; Lynch TJ; Lara PN; Cho J; Yanagihara RH; Vrindavanam N; Chowhan NM; Gadgeel SM; Pennell NA; Funke R; Mitchell B; Wakelee HA; Miller VA
    J Thorac Oncol; 2012 Jan; 7(1):219-26. PubMed ID: 22011666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer.
    Sacher AG; Le LW; Lara-Guerra H; Waddell TK; Sakashita S; Chen Z; Kim L; Zhang T; Kamel-Reid S; Salvarrey A; Darling G; Yasufuku K; Keshavjee S; de Perrot M; Shepherd FA; Liu G; Tsao MS; Leighl NB
    Oncotarget; 2016 May; 7(18):25632-9. PubMed ID: 27028852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M; Okamoto I; Nakagawa K
    Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.